Sustained blood pressure control with controlled-release isradipine

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Hypertension Research

Background:

• Essential hypertension affects a significant portion of the adult population worldwide.
• Controlled blood pressure is crucial for preventing cardiovascular complications.
• Existing antihypertensive treatments have varying efficacy and side effect profiles.

Purpose of the Study:

• To evaluate the efficacy and safety of different doses of a new controlled-release formulation of isradipine (isradipine-CR, ICR).
• To compare the effects of ICR against a placebo in patients with mild to moderate essential hypertension.
• To determine the dose-response relationship for ICR in blood pressure reduction.

Main Methods:

• A placebo-controlled study involving 402 randomized patients with essential hypertension (stages 1 and 2).
• Patients received varying doses of isradipine-CR (5, 10, 15, 20 mg) or placebo once daily.
• Blood pressure measurements were taken, and clinical side effects were monitored throughout the study.

Main Results:

• All doses of isradipine-CR significantly decreased blood pressure compared to placebo.
• Doses of 10, 15, and 20 mg of isradipine-CR showed a statistically significant greater effect (P < .001).
• Mild ankle edema was the most frequent dose-dependent side effect, occurring in 35.5% of patients on the 20-mg ICR dose.

Conclusions:

• Isradipine-CR is a long-acting and effective antihypertensive agent.
• Higher doses (10, 15, 20 mg) of isradipine-CR provide superior blood pressure control.
• Isradipine-CR is generally well-tolerated in patients with mild to moderate essential hypertension.